Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.oret.2020.10.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development and validation of CNN-MLP models for predicting anti-VEGF therapy outcomes in diabetic macular edema.
Sci Rep
December 2024
Eye School, Chengdu University of Traditional Chinese Medicine, Chengdu, 610000, Sichuan Province, China.
Diabetic macular edema (DME) is a common complication of diabetes that can lead to vision loss, and anti-vascular endothelial growth factor (anti-VEGF) therapy is the standard of care for DME, but the treatment outcomes vary widely among patients. This study collected optical coherence tomography (OCT) images and clinical data from DME patients who received anti-VEGF treatment to develop and validate deep learning (DL) models for predicting the anti-VEGF outcomes in DME patients based on convolutional neural network (CNN) and multilayer perceptron (MLP) combined architecture by using multimodal data. An Xception-MLP architecture was utilized to predict best-corrected visual acuity (BCVA), central subfield thickness (CST), cube volume (CV), and cube average thickness (CAT).
View Article and Find Full Text PDFRetrospective analysis of the etiology and drugs for vitreous hemorrhage caused by non-diabetic retinopathy and non-traumatic factors.
Hum Exp Toxicol
November 2024
Department of Fundus Disease, Tangshan Ophthalmology Hospital, Tangshan City, China.
Objective: To retrospectively analyze the etiology of non-diabetic retinopathy (DR) and non-traumatic vitreous haemorrhage (VH), and the effects of different anti-vascular endothelial growth factor (VEGF) drugs.
Methods: A retrospective analysis was conducted on VH patients diagnosed as non-diabetic retinopathy or trauma. Among 101 patients treated with anti-VEGF drugs, there were 48 cases in the Conbercept group and 53 cases in the Ranibizumab group.
The analysis of foveal microvascular anomalies in retinopathy of prematurity after anti-vascular endothelial growth factor therapy using optical coherence tomography angiography.
BMC Ophthalmol
November 2024
Department of Ophthalmology, Peking University People's Hospital, Eye Disease and Optometry Institute, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University Health Science Center, No. 11 Xizhimen South Street, Xicheng District, Beijing, China.
Background: To investigate the quantitative vascular and structural differences in the foveal region of the eyes in retinopathy of prematurity children with or without anti-vascular endothelial growth factor (VEGF) therapy and healthy children using optical coherence tomography angiography (OCTA).
Methods: This cross-sectional study analyzed 75 eyes from 44 subjects, categorized into four groups: ROP children treated with Conbercept or Ranibizumab, spontaneously regressed ROP, and healthy age-matched children. Using spectral-domain OCT and OCTA, we assessed parameters like central foveal thickness (CFT), foveal avascular zone (FAZ), superficial/deep capillary plexus (SCP/DCP), and choroidal vessel density (VD) at the fovea.
Short-term intraocular pressure changes after intravitreal aflibercept 2 mg, aflibercept 8 mg and faricimab: a prospective, comparative study.
Br J Ophthalmol
November 2024
Ophthalmology, Institute of Clinical Neurosciences of Southern Switzerland (INSI), Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland
Background/aims: Intravitreal injection (IVT) of anti-vascular endothelial growth factor agents is the standard of care for several retinal diseases but can cause intraocular pressure (IOP) elevations. This study investigates short-term postinjection IOP changes following aflibercept 8 mg and faricimab, compared with aflibercept 2 mg.
Methods: This observational, prospective study included 90 patients with age-related macular degeneration or diabetic macular oedema, divided into three groups, receiving aflibercept 2 mg, aflibercept 8 mg or faricimab.
Development and Novel Therapeutics in Diabetic Retinopathy.
Curr Diabetes Rev
October 2024
Department of Life Sciences, School of Pharmacy, International Medical University, Malaysia.
Diabetic retinopathy (DR) is a complication of diabetes mellitus which causes retinal damage which when left untreated will cause visual problems. As the prevalence of DR increases over the years, there is a need to optimise the currently available treatments as well as developing novel drugs to improve the therapy provided for the patients in the clinical practice. Several pharmacological therapies like, anti-vascular endothelial growth factor and anti-inflammatory therapies which include intravitreal, and implant of corticosteroids are significant in the management to decrease the risk of DR-related vision impairment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!